Diabesity Rounds

Efinopegdutide improves MASH histology at 52 weeks in a phase 2b trial

In adults with MASH and stage 2-3 fibrosis, once-weekly efinopegdutide led to more MASH resolution than placebo at week 52. Stopping treatment because of adverse events was most common at 10 mg.

Illustration. Not a photograph of the study.

At a glance

  • MASH resolution without worsening of fibrosis at week 52: 56%, 63% and 61% with efinopegdutide 4, 7 and 10 mg, versus 13% with placebo.
  • Fibrosis improvement of at least one stage was significantly higher than placebo at 4 mg and 7 mg, but not significantly different from placebo at 10 mg (p=0.072).
  • Gastrointestinal adverse events were most common at 10 mg, where nine (11%) of 79 participants stopped treatment because of adverse events.

Key result

MASH resolution at week 52 was 56% to 63% with efinopegdutide versus 13% with placebo.

MASH resolution without worsening of fibrosis, Week 52 (% of participants)

Placebo13.0
efinopegdutide 4 mg56
efinopegdutide 7 mg63
efinopegdutide 10 mg61

381 participants · 52 weeks · p<0.0001 vs placebo, all doses

Numbers as reported in the source.

The study

This was a phase 2b, randomised, placebo-controlled, double-blind study published in the Lancet. It ran at 176 academic and community centres in 26 countries. It enrolled adults aged 18 years or older with biopsy-confirmed, non-cirrhotic MASH and stage 2 or stage 3 fibrosis.

Efinopegdutide is a once-weekly GLP-1-glucagon receptor co-agonist. The authors describe a relative receptor potency balance of approximately 2:1. It is described as under development for MASH.

Participants were randomised 1:1:1:1:1 to efinopegdutide 4 mg, 7 mg or 10 mg, placebo, or open-label semaglutide 2.4 mg. All were given subcutaneously once weekly. In total, 386 people were randomised and 381 received at least one dose and were analysed. Of these, 239 (63%) had F2 fibrosis and 142 (37%) had F3 fibrosis. Mean age was 53 years (SD 13). The primary endpoint was MASH resolution without worsening of fibrosis at week 52. Missing end-of-treatment biopsies were counted as failures. The study was funded by Merck Sharp & Dohme, a subsidiary of Merck & Co.

What they found

MASH resolution without worsening of fibrosis occurred in 31 (56%) of 55 participants on 4 mg, 31 (63%) of 49 on 7 mg and 35 (61%) of 57 on 10 mg. With placebo it occurred in seven (13%) of 53. All three efinopegdutide doses were significantly better than placebo (p<0.0001 for each). In the semaglutide arm, 26 (53%) of 49 participants met this endpoint.

The key secondary endpoint was fibrosis improvement of at least one stage without worsening of steatohepatitis. It occurred in 32 (43%) of 75 on 4 mg, 39 (52%) of 75 on 7 mg and 26 (34%) of 77 on 10 mg. With placebo it occurred in 16 (21%) of 77. The 4 mg dose was significantly better than placebo (p=0.0038) and so was the 7 mg dose (p<0.0001). The 10 mg dose was not significantly different from placebo (difference 13.0 percentage points, 95% CI -1.2 to 26.8; p=0.072). In the semaglutide arm, 16 (25%) of 65 met this endpoint.

The most frequent adverse events with efinopegdutide were gastrointestinal, with the highest rates at 10 mg. Adverse events led to stopping treatment in nine (11%) of 79 participants on 10 mg, in 3% to 4% on the other efinopegdutide doses, and in one (1%) on placebo.

How much weight to give it

The design is strong for a phase 2b study: randomised, double-blind and placebo-controlled, with biopsy endpoints and missing biopsies counted as failures. The authors say the results support the potential utility of efinopegdutide in MASH. They judge the 7 mg dose to have the most favourable benefit-risk profile.

There are limits. The endpoints are histological, which are surrogate outcomes. The abstract does not report liver-related clinical events or follow-up beyond 52 weeks. Semaglutide was given open-label, and the abstract does not report a formal comparison between semaglutide and efinopegdutide, so no conclusion about which is better can be drawn. The abstract also does not explain why the numbers analysed differ between the two endpoints. The study was funded by Merck Sharp & Dohme, a subsidiary of Merck & Co.

For your clinic

This result does not change practice now. Efinopegdutide is described as under development, and the abstract says nothing about its availability.

For colleagues who see patients with MASH and significant fibrosis, the trial shows that efinopegdutide improved MASH resolution without worsening of fibrosis versus placebo at 52 weeks. Stopping treatment because of adverse events was more frequent at 10 mg than at the other doses. Read the full paper before drawing conclusions about safety. In particular, check the gastrointestinal adverse events, the reasons for stopping treatment and any effects on weight and glucose, which the abstract does not report.

Source

Efficacy and safety of efinopegdutide in adults with metabolic dysfunction-associated steatohepatitis and stage 2-3 fibrosis: a phase 2b, randomised, placebo-controlled study.

Lawitz E, Wong VW, Shankar RR et al.. Lancet (London, England). 9 November 2026

Read the source · DOI 10.1016/S0140-6736(26)02043-X

Cite this report: Diabesity Rounds. Efinopegdutide improves MASH histology at 52 weeks in a phase 2b trial. 2026. doi:10.5281/zenodo.24236969

Teaching a session? Download this report as a slide (PNG, free to use with credit).

For registered medical practitioners. This report summarises published research and is not advice for individual patients. Read the full paper and current guidelines before changing practice. Found an error? Write to editor@diabesityrounds.com; see our corrections and editorial policy.

More on fatty liver (masld)

Go deeper